论文部分内容阅读
肝切除术(hepatic resection,HR)在肝细胞性肝癌(hepatocellular carcinoma,HCC)根治性治疗中应用最广。在HCC的各种临床分期系统中,应用最广泛的是巴塞罗那临床肝癌(barcelona clinic liver cancer,BCLC)分期系统,欧洲肝脏研究协会和美国肝病研究协会指南的制订正是基于这一系统。这些指南推荐,HR仅适用于早期HCC,而对于中晚期HCC患者则更适合于经肝动脉化疗栓塞(transarterial chemoembolization,TACE)治疗。最新的一些发表在Lancet、J Hepatol、Semin Liver Dis期刊
Hepatic resection (HR) is widely used in radical treatment of hepatocellular carcinoma (HCC). It is based on this system that the most widely used clinical staging system for HCC is the development of the Barcelona Clinic Liver Cancer (BCLC) staging system, the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. These guidelines recommend that HR is only applicable to early HCC and is more suitable for transarterial chemoembolization (TACE) for advanced HCC. Some of the latest are published in Lancet, J Hepatol, Semin Liver Dis Journal